Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib for Refractory Immune-related Hematologic Toxicities in Advanced Lung Cancer
NCT07303881Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golidocitinib in hematologic toxicity (HT), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Clinical remission rate of immune-related hematologic toxicities at 12 weeks. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
hematologic toxicity (HT)
Beyond the preview
Go deeper on NCT07303881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07303881.